NeuroPhage Pharmaceuticals, Inc., a Cambridge, Massachusetts-based biotechnology company, closed $10.0m in an extension of its Series D private equity financing.
This additional funding (from new investors) brought total Series D round to $27.0m.
The company intends to use the funds to advance its lead drug candidate, NPT088, into clinical studies in Alzheimer’s disease by the end of 2015 and to advance innovative compounds for other diseases of protein misfolding.
Led by Jonathan Solomon, Chief Executive Officer, and Franz Hefti, President and Chief Operating Officer, NeuroPhage leverages novel and proprietary GAIM (General Amyloid Interaction Motif) technology to advance NPT088 to simultaneously target multiple types of misfolded proteins found in many diseases of aging, including Alzheimer’s and Parkinson’s diseases, as well as peripheral diseases, including the systemic amyloidoses.
FinSMEs
14/01/2015